Trial Information

Summary: A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Status: Recruiting

Protocol Number: NO18674

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: "An open-label, multiple ascending dose study to determine the maximum tolerated dose of R1530 in patients with advanced solid tumors."

Brief Summary: This study will determine the maximum tolerated dose, and assess the safety, tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors. R1530 will be administered daily for 14 days at the starting dose; this dose will be escalated in subsequent cohorts of patients, after a satisfactory assessment of safety and tolerability of the previous dose, until the maximum tolerated dose is reached. The anticipated time on study treatment is until disease progression, and the target sample size is <100 individuals. Target sample size is 104.

Study Phase: I

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Single Group
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Neoplasms

Intervention Type: Drug

Intervention Name: R1530

Primary Outcome: 1. Maximum tolerated dose Time frame: Throughout study

Key Secondary Outcomes: 1. AEs, laboratory parameters Time frame: Throughout study 2. Plasma levels of R1530 Time frame: Throughout study 3. Tumor assessments Time frame: Every 2 cycles of treatment

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • cancer not amenable to curative treatment (ie advanced and/or metastatic);
  • measurable or evaluable disease;
  • adequate cardiac, hepatic and renal function.

Exclusion Criteria:

  • patients with known CNS metastases;
  • serious cardiovascular illness or other medical conditions;
  • prior chemotherapy, radiotherapy or immunotherapy within 28 days of start of treatment , or hormone therapy within 14 days of start of treatment;
  • inability to swallow oral medications, or impaired gastrointestinal absorption.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: October, 2005

Trial Registration Date: 06/27/2007

Date Last Updated: 07/15/2008

Link To Trial Results

Contact:

Research Site:
Located in:
Houston, TX 77024
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 2:32:59 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA